title: Persistence in the treatment of overactive bladder syndrome (OAB) with mirabegron in a multicenter clinical study.
abstract: OBJECTIVE
  The objective of this project was to evaluate treatment persistence in patients being treated for overactive bladder syndrome (OAB) with mirabegron, employing clinical follow-up in a prospective, multicenter study.
  
  
  METHODS
  This is an analysis of patients who started treatment with mirabegron between May and September 2014 and were evaluated 1year after treatment commenced. During this evaluation we determined how many patients stopped treatment and established their reasons for discontinuation.
  
  
  RESULTS
  206 patients being treated for OAB with mirabegron were evaluated a year after starting treatment. It emerged that 60 patients (29.1%) had discontinued the treatment, citing the following reasons: 24/60 insufficient treatment efficacy, 26/60 other reasons, while 10 members of the group discontinued treatment because of side effects. 75 out of 206 patients were ≤60 years old and 28% terminated the study prematurely: 131 out of 206 were >60years old and 29.2% terminated the study prematurely. In the group of patients without previous OAB treatment 35.7% discontinued treatment with mirabegron, while 28.1% of patients with previous anticholinergic treatment discontinued treatment.
  
  
  CONCLUSIONS
  In our clinical prospective multicenter study, persistence in treatment with mirabegron reached a figure of 71%.
authors.affiliation: Department of Obstetrics and Gynecology, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Czechia. Electronic address: martan@vfn.cz.
authors.forename: Alois
authors.initials: A
authors.lastname: Martan
authors.affiliation: Department of Obstetrics and Gynecology, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Czechia. Electronic address: masata@volny.cz.
authors.forename: Jaromir
authors.initials: J
authors.lastname: Masata
authors.affiliation: Department of Urology, University Hospital in Ostrava, Czechia. Electronic address: jan.krhut@fno.cz.
authors.forename: Jan
authors.initials: J
authors.lastname: Krhut
authors.affiliation: Department of Urology, Thomayer Hospital in Prague, Czechia. Electronic address: roman.zachoval@ftn.cz.
authors.forename: Roman
authors.initials: R
authors.lastname: Zachoval
authors.affiliation: Department of Urology, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Czechia. Electronic address: tomas.hanus@lf1.cuni.cz.
authors.forename: Tomas
authors.initials: T
authors.lastname: Hanus
authors.affiliation: Department of Obstetrics and Gynecology, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Czechia. Electronic address: kamil@svabik.cz.
authors.forename: Kamil
authors.initials: K
authors.lastname: Svabik
mesh_terms: D000083:Acetanilides / Q000627:therapeutic use*; D058667:Adrenergic beta-3 Receptor Agonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013844:Thiazoles / Q000627:therapeutic use*; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*; D055815:Young Adult; D016903:Drug Monitoring
chemical_list: D000083:Acetanilides; D058667:Adrenergic beta-3 Receptor Agonists; D013844:Thiazoles; C520025:mirabegron
keywords: Antimuscarinic; Mirabegron; Overactive bladder; Persistence